These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Treatment of acute lymphoblastic leukemia in children according to the ALL-BFM-90m protocol in the Russian Federation and the Republic of Belarus].
    Author: Miakova NV, Aleĭnikova OV, Hartmann R, Rudneva AE, Trubina NM, Fechina LG, Timakov AM, Shamardina AV, Lebedev VV, Varfolomeeva SIu, Dudkin SD, Dyshlevaia ZM, Timofeeva VN, Rumiantsev AG, Henze H, Karachunskiĭ AI.
    Journal: Vopr Onkol; 2002; 48(3):347-51. PubMed ID: 12455360.
    Abstract:
    Prognosis for children treated according to the BFM-90m protocol (Berlin-Frankfurt-Munster Group) for acute lymphoblastic leukemia (ALL) improved significantly as compared with previous modalities. Methotrexate was used in the dose of 1,000 mg/m2, 36 h. The paper presents the 10-year results for this modification. Patients aged 0-15 years were treated at hematological hospitals of Moscow, other Russian towns and in Minsk, Belarus, (July 5, 1990-November 11, 2000). BFM-90m treatment was given to 682 children out of 1,326 with primary diagnosis of ALL; a comparative trial of the MB-91 protocol hed been carried out at the same clinics since 1991. During 10 years, recurrence-free survival was 72% while overall survival--77%. Toxicity of side-effects was tolerable. The BFM-90m treatment showed significantly better results in both countries.
    [Abstract] [Full Text] [Related] [New Search]